Navigation Links
Sangamo BioSciences Reports First Quarter 2012 Financial Results
Date:5/2/2012

s and presentation of data from clinical trials. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, the early stage of ZFP Therapeutic development, uncertainties related to the timing of initiation and completion of clinical trials, whether clinical trial results will validate and support the safety and efficacy of ZFP Therapeutics, and the ability to establish strategic partnerships.  Further, there can be no assurance that the necessary regulatory approvals will be obtained or that Sangamo will be able to develop commercially viable gene based therapeutics. Actual results may differ from those projected in forward-looking statements due to risks and uncertainties that exist in the company's operations and business environments. These risks and uncertainties are described more fully in the company's Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q as filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date and will not be updated.SELECTED CONSOLIDATED FINANCIAL DATA(in thousands, except per share data)(unaudited)Three Months Ended Statement of Operations DataMarch 31, 20122011Revenues:Collaboration agreements

$ 1,663$ 1,487Research grants

1,579713Total revenues

3,2422,200Operating expenses:Research and development

7,2838,262General and administrative

3,2423,539Total operating expenses

10,52511,801Loss from operations

(7,283)(9,601)Interest and other income, net

1523Net loss

$ (7,268)$ (9,578)Basic and diluted net loss per common share

$ (0.14)$ (0.21)Shares used in computing basic and diluted net loss per common share

52,56745,461March 31, 2012December 31, 2011(Unaudited)Selected B
'/>"/>

SOURCE Sangamo BioSciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Sangamo BioSciences to Present at the UBS Global Life Sciences Conference
2. Sangamo BioSciences to Present at Two Upcoming Investor Conferences
3. Sangamo BioSciences Announces Third Quarter Conference Call and Webcast
4. Sangamo BioSciences Presents Data at ICAAC Demonstrating In Vivo Protection Against HIV Infection by CCR5-ZFN Therapeutic
5. Sangamo BioSciences Reports Third Quarter 2008 Financial Results
6. Sangamo BioSciences Announces Results From Diabetic Neuropathy Clinical Trial SB-509-601
7. Sangamo BioSciences Appoints Paul Cleveland to Its Board of Directors and Chair of Audit Committee
8. Sangamo BioSciences to Webcast Annual Investor and Analyst Briefing and Presentation at Piper Jaffray Health Care Conference
9. Sangamo BioSciences to Present at the 27th Annual J.P. Morgan Healthcare Conference
10. Sigma-Aldrich and Sangamo BioSciences Announce the Achievement of Key Throughput Milestone in Research Reagents Agreement
11. Sangamo BioSciences Announces Fourth Quarter and Year-End 2008 Conference Call and Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... Aug. 21, 2014 Mathematic studies at the ... , and funded by the Jeffrey Epstein VI Foundation ... can be visually identified for elimination. These aggressive cells are ... which shows a topological map of what to look for ... research, for while tumor cells can be extracted from biopsy, ...
(Date:8/21/2014)... 21, 2014 Pursuit Solutions ( ... technology and services for Life Sciences sales and ... Use of New Commercial Sales Models” by Peter ... , The article examines some innovative models used ... being tested in the pharmaceutical market. Robinson grades ...
(Date:8/21/2014)... On Wednesday of last week RENU 28, the world's ... became available for purchase in Australia and New Zealand, and ... 28 works is, if you think about the definition of ... cellular renewal within your body. If you think about the ... cellular renewal. What RENU 28 does is it works with ...
(Date:8/20/2014)... time, chemists have succeeded in measuring vibrational motion of ... study reveals how vibration of a single molecule differs ... The study was performed at the University of California, ... of Jyvskyl works as a visiting fellow under professor ... The second team was lead by Professor Eric O. ...
Breaking Biology Technology:Science Power Jeffrey Epstein and Harvard University Fund Project to Visually Stop Tumor Growth 2Pursuit's Peter Robinson Publishes "Grading Pharma's Use of New Commercial Sales Models" 2RENU 28 Skin Care Now Available in Australia and New Zealand 2Seeing a molecule breathe 2
... VEENENDAAL, The Netherlands, June 2 ... today announced the creation,of an exclusive partnership and ... for an undisclosed sum. The two companies, headquartered ... the combination,will strengthen Nucletron,s position as global leader ...
... The American Institute of Aeronautics and Astronautics ... top emerging aerospace technologies. Developed by AIAA,s ... following: 1. "Greener Aviation" Technologies including emission ... the Federal Aviation Administration,s Continuous Low Emissions, Energy ...
... First Randomized Trial to Demonstrate Superior Clinical Benefit in Relapsed/Refractory Aggressive NHL , ... to treat Analysis results per FDA agreed upon Statistical Analysis Plan , ... Significant Increase in Complete Remission Rates 20% vs. 5.7%; p=0.021 ... Rate 37.1% vs. 14.3%; p=0.003 , ...
Cached Biology Technology:Dutch Medical Equipment Producer Nucletron Strengthens Leading Position in Cancer Radiation Therapy Market 2Dutch Medical Equipment Producer Nucletron Strengthens Leading Position in Cancer Radiation Therapy Market 3AIAA names top ten emerging aerospace technologies of 2009 2Pixantrone Significantly Increases Complete Remissions, Overall Response Rates, Frequency of Durable Remissions and Progression Free Survival in Patients with Relapsed and Refractory Aggressive Non-Hodgkin's Lymphoma 2Pixantrone Significantly Increases Complete Remissions, Overall Response Rates, Frequency of Durable Remissions and Progression Free Survival in Patients with Relapsed and Refractory Aggressive Non-Hodgkin's Lymphoma 3Pixantrone Significantly Increases Complete Remissions, Overall Response Rates, Frequency of Durable Remissions and Progression Free Survival in Patients with Relapsed and Refractory Aggressive Non-Hodgkin's Lymphoma 4Pixantrone Significantly Increases Complete Remissions, Overall Response Rates, Frequency of Durable Remissions and Progression Free Survival in Patients with Relapsed and Refractory Aggressive Non-Hodgkin's Lymphoma 5
(Date:8/21/2014)... use a previously unknown process for harvesting energy and ... a Penn State University scientist has discovered. The discovery ... plant growth, harvesting energy from the Sun, and understanding ... and other lakes worldwide. A paper describing the discovery ... edition of the journal Science on 21 ...
(Date:8/21/2014)... intake, health and quality of life of older adults ... the University of Waterloo receiving close to $1.5 million ... (CIHR). , Professor Heather Keller, of the Faculty ... research chair in nutrition and aging, will receive $979,000 ... in long-term care homes are poorly nourished. The project ...
(Date:8/21/2014)... consists of radiations in the 3.3 to 4.4 nanometre ... biological tissues. New theoretical findings show that it is ... These could be the basis of an optimal technique ... or to be used in high-precision spectroscopy. Now, a ... efficiently generate the harmonic radiationswhich are multiples of an ...
Breaking Biology News(10 mins):Hot-spring bacteria reveal ability to use far-red light for photosynthesis 2Hot-spring bacteria reveal ability to use far-red light for photosynthesis 3Grants will fund landmark aging research at Waterloo 2Water window imaging opportunity 2
... A drug made from the saliva of the Gila ... food. Researchers at the Sahlgrenska Academy, University of Gothenburg, ... ceased their cravings for both food and chocolate. ... diabetes are offered a pharmaceutical preparation called Exenatide, which ...
... 15, 2012) The Mass. Eye and Ear Curing Kids ... help the brain locate sound, identify genes that cause congenital ... for childhood eye cancer. The 2011/2012 Curing Kids Fund grants ... Sense-sation! gala. This year,s grant recipients are: , ...
... are used in gardens, burned for heat and energy, and ... grass family that includes corn, sorghum and sugarcane. Two new, ... (an ornamental that likely is a parent of Miscanthus ... sequencing the M. sinensis genome. The studies reveal ...
Cached Biology News:Drugs from lizard saliva reduces the cravings for food 2Mass. Eye and Ear announces Curing Kids Fund grant recipients 2Maps of Miscanthus genome offer insight into grass evolution 2Maps of Miscanthus genome offer insight into grass evolution 3
This BioSolution package is excellent for doing fluorescence thermal melt experiments on nucleic acids, studies involving biomolecular interactions, protein folding experiments, and more!...
anti-dansyl, rabbit IgG fraction *1 mg/mL* Secondary Detection; Anti-Dye and Anti-Hapten Antibodies...
MOUSE ANTI GUINEA PIG T-CELLS (PAN):FITC Immunogen: Guinea pig peritoneal T-cells...
... (100+kb), fosmid (40kb), and large plasmid insert ... othe BAC vector. On command 20-50 fold ... recombinant DNA purification. Available with blue-white screening ... for the highest insert stability. Kits include ...
Biology Products: